Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene-expression molecular subtyping of triple-negative breast cancer tumors

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103091 | GEO | 2017/08/27

SECONDARY ACCESSION(S): PRJNA400182

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Triple-negative breast cancer molecular subtyping and treatment progress.

Project description:Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.

| S-EPMC7285581 | biostudies-literature

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.

Project description:IntroductionTriple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer (BC) with limited options for therapy. TNBC is a heterogeneous disease and tumors have been classified into TNBC subtypes using gene expression profiling to distinguish basal-like 1, basal-like 2, immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen receptor (LAR), and one nonclassifiable group (called unstable).ObjectivesThe aim of this study was to verify the clinical relevance of molecular subtyping of TNBCs to improve the individual indication of systemic therapy.Patients and methodsMolecular subtyping was performed in 124 (82%) of 152 TNBC tumors that were obtained from a prospective, multicenter cohort including 1,270 histopathologically confirmed invasive, nonmetastatic BCs (NCT01592825). Treatment was guideline-based. TNBC subtypes were correlated with recurrence-free interval (RFI) and overall survival (OS) after 5 years of observation.ResultsUsing PAM50 analysis, 87% of the tumors were typed as basal with an inferior clinical outcome compared to patients with nonbasal tumors. Using the TNBCtype-6 classifier, we identified 23 (15%) of TNBCs as LAR subtype. After standard adjuvant or neoadjuvant chemotherapy, patients with LAR subtype showed the most events for 5-year RFI (66.7 vs. 80.6%) and the poorest probability of 5-year OS (60.0 vs. 84.4%) compared to patients with non-LAR disease (RFI: adjusted hazard ratio [aHR] = 1.87, 95% confidence interval [CI] 0.69-5.05, p = 0.211; OS: aHR = 2.74, 95% CI 1.06-7.10, p = 0.037).ConclusionMolecular analysis and subtyping of TNBC may be relevant to identify patients with LAR subtype. These cancers seem to be less sensitive to conventional chemotherapy, and new treatment options, including androgen receptor-blocking agents and immune checkpoint inhibitors, have to be explored.

| S-EPMC8740062 | biostudies-literature

Molecular subtyping of Triple negative Breast Cancer from Taiwanese

Project description:'Precision medicine' is a concept that by utilizing modern molecular diagnostics, an effective therapy is accurately applied for each cancer patient to improve their survival rates. The aim of this study was to compare the molecular subtypes of triple negative breast cancer (TNBC) between Taiwanese and other datasets.

2017-06-13 | GSE95700 | GEO

Metastasis in triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-03-13 | GSE111706 | GEO

FOXC1 in triple negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-06-14 | GSE213841 | GEO

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-01-07 | E-GEOD-63584 | biostudies-arrayexpress

Gene-expression molecular subtyping of triple-negative breast cancer tumors

Project description:Gene-expression molecular subtyping of triple-negative breast cancer tumors

| PRJNA400182 | ENA

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-12-23 | E-GEOD-76275 | biostudies-arrayexpress

Histone deacetylase inhibition in triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-02-14 | GSE92911 | GEO

H3K27me3 conditions chemotolerance in triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-02-15 | GSE164716 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data